Seminars in Hematology
Volume 46, Issue 3 , Pages 198-211 , July 2009

Advances in Antibacterial Therapy Against Emerging Bacterial Pathogens

  • Spyros Pournaras

      Affiliations

    • Department of Microbiology, Medical School, University of Thessaly, Larissa, Greece
    • ,
  • Elias Iosifidis

      Affiliations

    • Third Department of Pediatrics, Aristotle University School of Medicine, Thessaloniki, Greece
    • ,
  • Emmanuel Roilides

      Affiliations

    • Third Department of Pediatrics, Aristotle University School of Medicine, Thessaloniki, Greece
    • Corresponding Author InformationAddress correspondence to Emmanuel Roilides, MD, PhD, Third Department of Pediatrics, Aristotle University School of Medicine, Hippokration Hospital, Konstantinoupoleos 49, GR-546 42 Thessaloniki, Greece

References 

  1. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 6th ed.. Villanova, PA: CLSI; 2006;CLSI approved standard M7–A7
  2. Ikonomidis A, Michail G, Vasdeki A, Labrou M, Karavasilis V, Stathopoulos C, et al. In vitro and in vivo evaluations of oxacillin efficiency against mecA-positive oxacillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2008;52:3905–3908
  3. Chambers HF, Sachdeva M. Binding of beta-lactam antibiotics to penicillin-binding proteins in methicillin-resistant Staphylococcus aureus. J Infect Dis. 1990;161:1170–1176
  4. Duckworth GJ, Lothian JL, Williams JD. Methicillin-resistant Staphylococcus aureus: report of an outbreak in a London teaching hospital. J Hosp Infect. 1988;11:1–15
  5. Grundmann H, Aires-de-Sousa M, Boyce J, Tiemersma E. Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet. 2006;368:874–885
  6. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32:470–485
  7. Boucher HW, Corey GR. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008;46(Suppl 5):S344–S349
  8. Pournaras S, Slavakis A, Polyzou A, Sofianou D, Maniatis AN, Tsakris A. Nosocomial spread of an unusual methicillin-resistant Staphylococcus aureus clone that is sensitive to all non-β-lactam antibiotics, including tobramycin. J Clin Microbiol. 2001;39:779–781
  9. Nygaard TK, DeLeo FR, Voyich JM. Community-associated methicillin-resistant Staphylococcus aureus skin infections: advances toward identifying the key virulence factors. Curr Opin Infect Dis. 2008;21:147–152
  10. Diep BA, Chambers HF, Graber CJ, Szumowski JD, Miller LG, Han LL, et al. Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med. 2008;148:249–257
  11. Cosgrove SE, Carroll KC, Perl TM. Staphylococcus aureus with reduced susceptibility to vancomycin. Clin Infect Dis. 2004;39:539–545
  12. Appelbaum PC. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin Microbiol Infect. 2006;12(Suppl 1):16–23
  13. Sung JM, Lindsay JA. Staphylococcus aureus strains that are hypersusceptible to resistance gene transfer from enterococci. Antimicrob Agents Chemother. 2007;51:2189–2191
  14. Tiwari HK, Sen MR. Emergence of vancomycin resistant Staphylococcus aureus (VRSA) from a tertiary care hospital from northern part of India. BMC Infect Dis. 2006;6:156
  15. Papanicolaou GA, Meyers BR, Meyers J, Mendelson MH, Lou W, Emre S, et al. Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: risk factors for acquisition and mortality. Clin Infect Dis. 1996;23:760–766
  16. Matar MJ, Tarrand J, Raad I, Rolston KV. Colonization and infection with vancomycin-resistant Enterococcus among patients with cancer. Am J Infect Control. 2006;34:534–536
  17. Sahm DF, Marsilio MK, Piazza G. Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the Surveillance Network Database—USA. Clin Infect Dis. 1999;29:259–263
  18. Pournaras S, Malamou-Lada H, Maniati M, Mylona-Petropoulou D, Vagiakou-Voudris H, Tsakris A, et al. Persistence of a clone of glycopeptide-resistant Enterococcus faecalis among patients in an intensive care unit of a Greek hospital. J Antimicrob Chemother. 2004;53:109–112
  19. Hayden MK. Insights into the epidemiology and control of infection with vancomycin-resistant enterococci. Clin Infect Dis. 2000;31:1058–1065
  20. Maniatis AN, Pournaras S, Kanellopoulou M, Kontos F, Dimitroulia E, Papafrangas E, et al. Dissemination of clonally unrelated erythromycin- and glycopeptide-resistant Enterococcus faecium isolates in a tertiary Greek hospital. J Clin Microbiol. 2001;39:4571–4574
  21. Donskey CJ, Schreiber JR, Jacobs MR, Shekar R, Salata RA, Gordon S, et al. A polyclonal outbreak of predominantly VanB vancomycin-resistant enterococci in northeast Ohio (Northeast Ohio Vancomycin-Resistant Enterococcus Surveillance Program). Clin Infect Dis. 1999;29:573–579
  22. Leavis HL, Willems RJ, Top J, Spalburg E, Mascini EM, Fluit AC, et al. Epidemic and nonepidemic multidrug-resistant Enterococcus faecium. Emerg Infect Dis. 2003;9:1108–1115
  23. Scheetz MH, Knechtel SA, Malczynski M, Postelnick MJ, Qi C. Increasing incidence of linezolid-intermediate or -resistant, vancomycin-resistant Enterococcus faecium strains parallels increasing linezolid consumption. Antimicrob Agents Chemother. 2008;52:2256–2259
  24. DiazGranados CA, Jernigan JA. Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection. J Infect Dis. 2005;191:588–595
  25. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18:657–686
  26. Canton R, Coque TM. The CTX-M beta-lactamase pandemic. Curr Opin Microbiol. 2006;9:466–475
  27. Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev. 2007;20:440–458
  28. Rossolini GM, Luzzaro F, Migliavacca R, Mugnaioli C, Pini B, De Luca F, et al. First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. Antimicrob Agents Chemother. 2008;52:4023–4029
  29. Navon-Venezia S, Chmelnitsky I, Leavitt A, Schwaber MJ, Schwartz D, Carmeli Y. Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel. Antimicrob Agents Chemother. 2006;50:3098–3101
  30. Tsakris A, Kristo I, Poulou A, Themeli-Digalaki K, Ikonomidis A, Petropoulou D, et al. Evaluation of boronic acid disk tests for differentiating KPC-possessing Klebsiella pneumoniae isolates in the clinical laboratory. J Clin Microbiol. 2008;PMID:19073868
  31. CLSI document. 2007. Clinical and laboratory standard methods. Performance standards for antimicrobial susceptibility testing: seventeenth informational supplement. Wayne, PA: Clinical and Laboratory Standard Institute; 2007;M100-S17
  32. Paterson DL, Ko WC, Von Gottberg A, Casellas JM, Mulazimoglu L, Klugman KP, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol. 2001;39:2206–2212
  33. Tsakris A, Pournaras S, Woodford N, Palepou MF, Babini GS, Douboyas J, et al. Outbreak of infections caused by Pseudomonas aeruginosa producing VIM-1 carbapenemase in Greece. J Clin Microbiol. 2000;38:1290–1292
  34. Livermore DM. Of pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother. 2001;47:247–250
  35. Lee NY, Lee HC, Ko NY, Chang CM, Shih HI, Wu CJ, et al. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol. 2007;28:713–719
  36. Chan PC, Huang LM, Lin HC, Chang LY, Chen ML, Lu CY, et al. Control of an outbreak of pandrug-resistant Acinetobacter baumannii colonization and infection in a neonatal intensive care unit. Infect Control Hosp Epidemiol. 2007;28:423–429
  37. Go ES, Urban C, Burns J, Kreiswirth B, Eisner W, Mariano N, et al. Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet. 1994;344:1329–1332
  38. Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2006;50:2946–2950
  39. Navon-Venezia S, Leavitt A, Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2007;59:772–774
  40. Sung JY, Kwon KC, Park JW, Kim YS, Kim JM, Shin KS, et al. Dissemination of IMP-1 and OXA type beta-lactamase in carbapenem-resistant Acinetobacter baumannii. Korean J Lab Med. 2008;28:16–23
  41. Ikonomidis A, Ntokou E, Maniatis AN, Tsakris A, Pournaras S. Hidden VIM-1 metallo-beta-lactamase phenotypes among Acinetobacter baumannii clinical isolates. J Clin Microbiol. 2008;46:346–349
  42. Mendes RE, Bell JM, Turnidge JD, Castanheira M, Jones RN. Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among Acinetobacter spp. in Asia-Pacific nations: report from the SENTRY Surveillance Program. J Antimicrob Chemother. 2009;63:55–59
  43. Manfredi R. Update on the appropriate use of linezolid in clinical practice. Therapeut Clin Risk Manage. 2006;2:455–464
  44. Eliopoulos GM. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis. 2003;36:473–481
  45. Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptide or beta-lactam for treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis. 2008;8:53–66
  46. Falagas ME, Manta KG, Ntziora F, Vardakas KZ. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother. 2006;58:273–280
  47. Ntziora F, Falagas ME. Linezolid for the treatment of patients with central nervous system infection. Ann Pharmacother. 2007;41:296–308
  48. Gerson SL, Kaplan SL, Bruss JB, Le V, Arellano FM, Hafkin B, et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother. 2002;46:2723–2726
  49. Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis. 2006;43:180–187
  50. Smith PF, Birmingham MC, Noskin GA, Meagher AK, Forrest A, Rayner CR, et al. Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant gram-positive infections in cancer patients with neutropenia. Ann Oncol. 2003;14:795–801
  51. Jaksic B, Martinelli G, Perez-Oteyza J, Hartman CS, Leonard LB, Tack KJ. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis. 2006;42:597–607
  52. Tattevin P, Camus C. What can we learn from studies comparing linezolid with vancomycin in neutropenic patients when vancomycin dosages are not optimized?. Clin Infect Dis. 2006;42:1813–1814
  53. Muthaiyan A, Silverman JA, Jayaswal RK, Wilkinson BJ. Transcriptional profiling reveals that daptomycin induces the Staphylococcus aureus cell wall stress stimulon and genes responsive to membrane depolarization. Antimicrob Agents Chemother. 2008;52:980–990
  54. Hawkey PM. Pre-clinical experience with daptomycin. J Antimicrob Chemother. 2008;62(Suppl 3):iii7–iii14
  55. Poutsiaka DD, Skiffington S, Miller KB, Hadley S, Snydman DR. Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J Infect. 2007;54:567–571
  56. Sakoulas G, Golan Y, Lamp KC, Friedrich LV, Russo R. Daptomycin in the treatment of bacteremia. Am J Med. 2007;120(10 Suppl 1):S21–S27
  57. Lalani T, Boucher HW, Cosgrove SE, Fowler VG, Kanafani ZA, Vigliani GA, et al. Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2008;61:177–182
  58. Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis. 2005;191:2149–2152
  59. Pertel PE, Bernardo P, Fogarty C, Matthews P, Northland R, Benvenuto M, et al. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis. 2008;46:1142–1151
  60. Falagas ME, Giannopoulou KP, Ntziora F, Vardakas KZ. Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence. J Antimicrob Chemother. 2007;60:7–19
  61. Fowler VG, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653–665
  62. Mangili A, Bica I, Snydman DR, Hamer DH. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2005;40:1058–1060
  63. Cui L, Tominaga E, Neoh HM, Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50:1079–1082
  64. Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering RC, Eliopoulos GM. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother. 2006;50:1581–1585
  65. Linden PK. Vancomycin resistance: are there better glycopeptides coming?. Exp Rev Antiinfect Ther. 2008;6:917–928
  66. Laohavaleeson S, Kuti JL, Nicolau DP. Telavancin: a novel lipoglycopeptide for serious gram-positive infections. Exp Opin Invest Drugs. 2007;16:347–357
  67. Hegde S, Skinner R, Difuntorum S, Krause K. Efficacy of telavancin against hVISA infections in the neutropenic murine bacteremia model. [abstract B-1012]. 48th Annual Interscience Conference on Antimicrobial Agents and hemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) 46th Annual Meeting; Washington, DC 2008;
  68. Nannini EC, Stryjewski ME. A new lipoglycopeptide: telavancin. Exp Opin Pharmacother. 2008;9:2197–2207
  69. Stryjewski ME, Graham DR, Wilson SE, O'Riordan W, Young D, Lentnek A, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis. 2008;46:1683–1693
  70. Kim SJ, Cegelski L, Stueber D, Singh M, Dietrich E, Tanaka KS, et al. Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus. J Mol Biol. 2008;377:281–293
  71. Poulakou G, Giamarellou H. Oritavancin: a new promising agent in the treatment of infections due to gram-positive pathogens. Exp Opin Invest Drugs. 2008;17:225–243
  72. Crandon J, Nicolau DP. Oritavancin: a potential weapon in the battle against serious gram-positive pathogens. Future Microbiol. 2008;3:251–263
  73. Hartman CS, Wasilewski MM, Bates BM. Oritavancin in the treatment of complicated skin and skin structure infections (cSSSI): combined results of two phase 3 multinational trials. [abstract L 1514]. 48th Annual Interscience Conference on Antimicrobial Agents and hemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) 46th Annual Meeting; Washington, DC 2008;
  74. Bennett JW, Lewis JS, Ellis MW. Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review. Therapeut Clin Risk Manage. 2008;4:31–40
  75. Poulakou G, Giamarellou H. Doripenem: an expected arrival in the treatment of infections caused by multidrug-resistant gram-negative pathogens. Exp Opin Invest Drugs. 2008;17:749–771
  76. Kattan JN, Villegas MV, Quinn JP. New developments in carbapenems. Clin Microbiol Infect. 2008;14:1102–1111
  77. Gettig JP, Crank CW, Philbrick AH. Faropenem medoxomil. Ann Pharmacother. 2008;42:80–90
  78. Koga T, Masuda N, Kakuta M, Namba E, Sugihara C, Fukuoka T. Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2008;52:2849–2854
  79. Pliatsika V, Afkou Z, Protonotariou E, Sofianou D. In vitro activity of tigecycline against metallo-beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother. 2007;60:1406–1407
  80. Jones CH, Tuckman M, Howe AY, Orlowski M, Mullen S, Chan K, et al. Diagnostic PCR analysis of the occurrence of methicillin and tetracycline resistance genes among Staphylococcus aureus isolates from phase 3 clinical trials of tigecycline for complicated skin and skin structure infections. Antimicrob Agents Chemother. 2006;50:505–510
  81. Noviello S, Ianniello F, Leone S, Fiore M, Esposito S. In vitro activity of tigecycline: MICs, MBCs, time-kill curves and post-antibiotic effect. J Chemother (Florence, Italy). 2008;20:577–580
  82. Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother. 2006;58:1221–1229
  83. Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infect Dis. 2006;43:518–524
  84. Conte JE, Golden JA, Kelly MG, Zurlinden E. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents. 2005;25:523–529
  85. Karageorgopoulos DE, Kelesidis T, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother. 2008;62:45–55
  86. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis. 2005;41(Suppl 5):S354–S367
  87. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis. 2005;41(Suppl 5):S341–S353
  88. Tanaseanu C, Bergallo C, Teglia O, Jasovich A, Oliva ME, Dukart G, et al. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis. 2008;61:329–338
  89. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE! (An update from the Infectious Diseases Society of America). Clin Infect Dis. 2009;48:1–12
  90. Florescu I, Beuran M, Dimov R, Razbadauskas A, Bochan M, Fichev G, et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother. 2008;62(Suppl 1):i17–i28
  91. Vasilev K, Reshedko G, Orasan R, Sanchez M, Teras J, Babinchak T, et al. A phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J Antimicrob Chemother. 2008;62(Suppl 1):i29–i40
  92. Chemlay RF, Hanmod S, Mulanovich V, Adachi J, Rolston K, Raad I, et al. Tigecycline usage in cancer patients with serious infections: a report on 110 cases from a single institution. [abstract K-1413]. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) 46th Annual Meeting; Washington, DC 2008;
  93. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect Dis. 2006;6:589–601
  94. Michalopoulos A, Falagas ME. Colistin and polymyxin B in critical care. Crit Care Clin. 2008;24:377–391
  95. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother. 1999;33:960–967
  96. http://clinicaltrials. gov/ct2/results?term=colistin
  97. Kallel H, Hergafi L, Bahloul M, Hakim A, Dammak H, Chelly H, et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intens Care Med. 2007;33:1162–1167
  98. Rios FG, Luna CM, Maskin B, Saenz Valiente A, Lloria M, Gando S, et al. Ventilator-associated pneumonia due to colistin susceptible-only microorganisms. Eur Respir J. 2007;30:307–313
  99. Hachem RY, Chemaly RF, Ahmar CA, Jiang Y, Boktour MR, Rjaili GA, et al. Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients. Antimicrob Agents Chemother. 2007;51:1905–1911
  100. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, Barrero-Almodovar AE, Garcia-Garmendia JL, Bernabeu-Wittel IM, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis. 2003;36:1111–1118
  101. Reina R, Estenssoro E, Saenz G, Canales HS, Gonzalvo R, Vidal G, et al. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intens Care Med. 2005;31:1058–1065
  102. Michalopoulos A, Fotakis D, Virtzili S, Vletsas C, Raftopoulou S, Mastora Z, et al. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant gram-negative bacteria: a prospective study. Respir Med. 2008;102:407–412
  103. Levin AS, Barone AA, Penco J, Santos MV, Marinho IS, Arruda EA, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis. 1999;28:1008–1011
  104. Linden PK, Kusne S, Coley K, Fontes P, Kramer DJ, Paterson D. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2003;37:e154–e160
  105. Markou N, Apostolakos H, Koumoudiou C, Athanasiou M, Koutsoukou A, Alamanos I, et al. Intravenous colistin in the treatment of sepsis from multiresistant gram-negative bacilli in critically ill patients. Crit Care (London, England). 2003;7:R78–R83
  106. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. Colistin treatment in patients with ICU-acquired infections caused by multiresistant gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect. 2005;11:115–121
  107. Falagas ME, Rizos M, Bliziotis IA, Rellos K, Kasiakou SK, Michalopoulos A. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis. 2005;5:1
  108. Landman D, Georgescu C, Martin DA, Quale J. Polymyxins revisited. Clin Microbiol Rev. 2008;21:449–465
  109. Song JY, Cheong HJ, Lee J, Sung AK, Kim WJ. Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model. Intern J Antimicrob Agents. 2009;33:33–39
  110. Petrosillo N, Ioannidou E, Falagas ME. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin Microbiol Infect. 2008;14:816–827
  111. Craig WA, Ebert SC. Continuous infusion of beta-lactam antibiotics. Antimicrob Agents Chemother. 1992;36:2577–2583
  112. Nicolau DP. Pharmacodynamic optimization of beta-lactams in the patient care setting. Crit Care (London, England). 2008;12(Suppl 4):S2
  113. Mouton JW, Vinks AA. Continuous infusion of beta-lactams. Curr Opin Crit Care. 2007;13:598–606
  114. Kasiakou SK, Sermaides GJ, Michalopoulos A, Soteriades ES, Falagas ME. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis. 2005;5:581–589
  115. Bodey GP, Ketchel SJ, Rodriguez V. A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med. 1979;67:608–616
  116. Lodise TP, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis. 2007;44:357–363

PII: S0037-1963(09)00062-6

doi: 10.1053/j.seminhematol.2009.03.007

Seminars in Hematology
Volume 46, Issue 3 , Pages 198-211 , July 2009

Article Tools